lacutoclax

LP-108 (lacutoclax) is an orally bioavailable, highly potent, and selective small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2). By binding to and inhibiting BCL-2, LP-108 restores apoptotic processes in tumor cells, leading to pro-apoptotic and antineoplastic effects. It has demonstrated comparable or greater in vitro potency than venetoclax, the FDA-approved BCL-2 inhibitor. LP-108 is being developed primarily for hematologic malignancies such as relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), non-Hodgkin’s lymphoma (NHL), and chronic lymphocytic leukemia (CLL). Clinical trials have evaluated its use both as monotherapy and in combination with azacitidine.

Other names

Lactocletas